Elevated intraocular pressure, ocular hypertension, open-angle glaucoma

Active Ingredient: Travoprost

Indication for Travoprost

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma.

For this indication, competent medicine agencies globally authorize below treatments:

1 drop once daily

Route of admnistration

Ophthalmic

Defined daily dose

1 - 1 {drops}

Dosage regimen

From 1 To 1 {drops} once every day

Detailed description

The dose is one drop of travoprost in the conjunctival sac of the affected eye(s) once daily. Optimal effect is obtained if the dose is administered in the evening.

Nasolacrimal occlusion or gently closing the eyelid after administration is recommended. This may reduce the systemic absorption of medicinal products administered via the ocular route and result in a decrease in systemic adverse reactions.

If more than one topical ophthalmic medicinal product is being used, the medicinal products must be administered at least 5 minutes apart.

If a dose is missed, treatment should be continued with the next dose as planned. The dose should not exceed one drop in the affected eye(s) daily.

When substituting another ophthalmic antiglaucoma medicinal product with travoprost, the other medicinal product should be discontinued and travoprost should be started the following day.

Paediatric population

Travoprost can be used in paediatric patients from 2 months to <18 years at the same posology as in adults. However, data in the age group 2 months to <3 years (9 patients) is limited.

The safety and efficacy of travoprost in children below the age of 2 months have not been established. No data are available.

Active ingredient

Travoprost

Travoprost, a prostaglandin F analogue, is a highly selective full agonist which has a high affinity for the prostaglandin FP receptor, and reduces the intraocular pressure by increasing the outflow of aqueous humour via trabecular meshwork and uveoscleral pathways.

Read more about Travoprost

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.